Narrow search
Showing 1 - 10 of 160,193
Cover Image
Advances in Cancer Therapeutics and Patient Access to New Drugs
Dranitsaris, George; Truter, Ilse; Lubbe, Martie S.; … - In: PharmacoEconomics 29 (2011) 3, pp. 213-224
Globally, there are approximately 7.4 million cancer deaths annually, approximately 13% of deaths from all causes …. Cancer is a disease of older people and, as the population ages over the next 10-20 years, we can expect an increase in the … cancer incidence. Encouragingly, cancer mortality has stabilized in many countries. Part of this success may be attributed to …
Persistent link: https://www.econbiz.de/10010614407
Cover Image
Measuring the Externality of Antibacterial Use from Promoting Antimicrobial Resistance
Kaier, Klaus; Frank, Uwe - In: PharmacoEconomics 28 (2010) 12, pp. 1123-1128
prioritizing prevention methods. …
Persistent link: https://www.econbiz.de/10008725817
Cover Image
Influenza Vaccination in Healthy Working Adults in Russia: Observational Study of Effectiveness and Return on Investment for the Employer
At'kov, O. Yu. Atkov; Azarov, A.V.; Zhukov, D.A.; … - In: Applied Health Economics and Health Policy 9 (2011) 2, pp. 89-99
Background: All age groups are affected by influenza infection, resulting in significant medical and economic burden. Influenza infection of healthy working adults can have a marked effect on companies due to lost work days and reduced productivity. Studies in corporate settings have shown that...
Persistent link: https://www.econbiz.de/10010614270
Cover Image
Cost Effectiveness of Pneumococcal Conjugate Vaccination against Acute Otitis Media in Children: A Review
Boonacker, Chantal W.B.; Broos, Pieter H.; Sanders, … - In: PharmacoEconomics 29 (2011) 3, pp. 199-211
While pneumococcal conjugate vaccines have shown to be highly effective against invasive pneumococcal disease, their potential effectiveness against acute otitis media (AOM) might become a major economic driver for implementing these vaccines in national immunization programmes. However, the...
Persistent link: https://www.econbiz.de/10010614297
Cover Image
Rotavirus Vaccine RIX4414 (Rotarix™): A Pharmacoeconomic Review of its Use in the Prevention of Rotavirus Gastroenteritis in Developing Countries
Plosker, Greg L. - In: PharmacoEconomics 29 (2011) 11, pp. 989-1009
This article provides an overview of the clinical profile of rotavirus vaccine RIX4414 (Rotarix™) in the prevention of …
Persistent link: https://www.econbiz.de/10010614303
Cover Image
The Authors' Reply
Kapoor, Alok; Radhakrishnan, Nila; Smith, Kenneth J. - In: PharmacoEconomics 28 (2010) 9, pp. 782-784
Persistent link: https://www.econbiz.de/10010614307
Cover Image
The Authors' Reply
McCullagh, Laura; Tilson, Lesley; Walsh, Cathal; Barry, … - In: PharmacoEconomics 28 (2010) 9, pp. 784-785
Persistent link: https://www.econbiz.de/10010614318
Cover Image
Posaconazole: A Pharmacoeconomic Review of its Use in the Prophylaxis of Invasive Fungal Disease in Immunocompromised Hosts
Lyseng-Williamson, Katherine A. - In: PharmacoEconomics 29 (2011) 3, pp. 251-268
Posaconazole (Noxafil) is an oral, second-generation, extended-spectrum triazole whose approved indications include prophylaxis of invasive fungal disease (IFD) in immunocompromised patients. In pivotal head-to-head trials, posaconazole was significantly more effective in preventing IFD than...
Persistent link: https://www.econbiz.de/10010614335
Cover Image
Cost Effectiveness of Venous Thromboembolism Pharmacological Prophylaxis in Total Hip and Knee Replacement:: A Systematic Review
Plumb, Jonathan M.; Clemens, Andreas; Monz, Brigitta U. - In: PharmacoEconomics 28 (2010) 9, pp. 781-782
Persistent link: https://www.econbiz.de/10010614396
Cover Image
Cost Effectiveness of Venous Thromboembolism Pharmacological Prophylaxis in Total Hip and Knee Replacement: A Systematic Review
Kapoor, Alok; Chuang, Warren; Radhakrishnan, Nila; … - In: PharmacoEconomics 28 (2010) 7, pp. 521-538
Total hip and knee replacements (THR and TKR) are high-risk settings for venous thromboembolism (VTE). This review summarizes the cost effectiveness of VTE prophylaxis regimens for THR and TKR. We searched MEDLINE (January 1997 to October 2009), EMBASE (January 1997 to June 2009) and the UK NHS...
Persistent link: https://www.econbiz.de/10008505440